Rheumatic Fever Clinical Trial
Official title:
Phase I Clinical Trial for Assessment of Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes in Healthy Volunteers
This is a double-blind, randomized, placebo-controlled phase I clinical trial with dose-escalation of a synthetic vaccine against Streptococcus pyogenes. The active component of this vaccine candidate is a synthetic polypeptide named StreptInCor designed to elicit humoral and cell-mediated immune responses. The vaccine will be formulated with Aluminium hydroxide in three different doses of StreptInCor (50 µg, 100µg, 200 µg). The proposed vaccination schedule is three doses (0, 1, 6 months). The doses will be escalated for the next group after safety review.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02407106 -
Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children
|
N/A | |
| Completed |
NCT03281863 -
Clinical Audit on the Managment in Assiut University Children Hospital
|
||
| Not yet recruiting |
NCT06259006 -
TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children
|
Phase 3 | |
| Recruiting |
NCT04316897 -
Prevalence of Rheumatic Heart Disease According to Revised Jones Criteria (2015) in Assiut Governate
|
||
| Completed |
NCT04798053 -
Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients
|
N/A | |
| Completed |
NCT02124109 -
The Genetic Basis of Acquired Heart Disease in Africa
|
||
| Recruiting |
NCT06400628 -
Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes
|
N/A |